Mar 14, 2022Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
Jan 10, 2022Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
Nov 29, 2021Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
Nov 10, 2021Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
Nov 09, 2021Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
Sep 27, 2021Verve Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference
